Overzicht richtlijnen, recente literatuur

Feochromocytoom

AdobeStock_54041095.jpg 19 augustus 2015 117 kB 560 × 169: Drawing of production cycle made by a hand

Lenders J. et al; Phaeochromocytoma; Lancet 2005 366: 665-675
Lenders J.; Pheochromocytoma – update on disease management; Ther Adv Endocrinol Metab 2012 3(1): 11-26
Pappachan J.M. et al; Diagnosis and management of pheochromocytoma: a practical guide to clinicians; Curr Hypertens Rep 2014 16: 442
Lenders J.W.M. et al; Biochemical diagnosis of pheochromocytoma; JAMA 2002 287(11): 1427-1433
Conzo G. et al; Current concepts of pheochromocytoma; Int J Surg 2014 12:469-474
Lefebvre M., Pheochromocytoma and paraganglioma syndromes: genetics and management update; Curr Oncol 2014 21(1): e8-e17
Taieb D. et al; Current approaches and recent developments in the management of head and neck paragangliomas; Endocrine Rev 2014 35(5): 795-819
Chen H. et al; The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma and medullary thyroid cancer; Pancreas 2010 39(6): 775-783
Eisenhofer G. et al; Diagnostic tests and biomarkers for pheochromocytoma and extra- adrenal paraganglioma: from routine laboratory methods to disease stratification; Endocr Pathol 2012 23:4-14
Mannelli M. et al; Subclinical phaeochromocytoma; Best Pract Res Clin Endocrinol Metab 2012 26(4): 507-515
Martucci V.L.; Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment; Curr Probl Cancer 2014 38(1): 7-41
Hodin R. et al; Diagnosis and management of pheochromocytoma; Cur Pro Surg 2014 51: 151-187
Ballav C. et al; Mini review: Pheochromocytomas causing the ectopic ACTH syndrome; Endocrine 2012 42: 69-73
Baysal B.E. et al; Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations; 2015 ERC-15-0226
Rao J.U. et al; Genotype-Specific Differences in the tumor Metabolite profile of Pheochromocytoma and Paraganglioma using untargeted and targeted Metabolomics; JCEM 2015 100(2): E214-E222
Lefebevre M. et al; Pheochromocytoma and paraganglioma syndromes: genetics and management update; Cur Oncology 2014 21(1): e8
King S. et al; Familial pheochromocytomas and Paragangliomas; Mol Cell Endocrinol. 2014 386(0): 92-100
Brito J.P. et al; Testing for germline mutations in sporadic pheochromocytoma/ paraganglioma: a systematic review; Clin Endocrinol 2015 82: 338-345
Martins R. et al; Paragangliomas/ Pheochromocytomas: Clinically oriented genetic testing; International journal of endocrinology volume 2014, ID 794187
Fishbein L. et al; Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing; Ann Surg Oncol.2013 May; 20(5): 1444- 1450
Kantorovich V. et al; SDH-related Pheochromocytoma and paraganglioma; Best Pract Res Clin Endocrinol Metab. 2010 249(3): 415-424
Papathomas T.G. et al; SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the study of Adrenal Tumors; Modern pathology 2015 28: 807-821
Mazza A. et al; anti- hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features; Endocrine 2014 45: 469-478
Niemeijer N.D. et al; Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta- analysis; Clin Endocrinol 2014 81, 642-651
Deutschbein T. et al; treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature; Clin Endocrinol 2015 82: 84-90
Schreinemakers J.M.J. et al; Retroperitoneal endoscopic adrenalectomy is safe and effective; British J surgery 2010; 97: 1667-1672
Fishbein L. et al; External beam Radiation therapy (ebrt) for patients with malignant pheochromocytoma and non-head and neck paraganglioma: combination with 131I-MIBG; Horm metab Res.2012 44(5): 405-410
Goers T.A. et al; Outcomes of resection of extra- adrenal pheochromocytomas/ paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma; Surg endosc 2013 27: 428-433
Ayala-Ramirez M. et al; treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas; JCEM 2012 97(11): 4040-4050
Ilias I. et al; A probabilistic assessment of the diagnosis of paraganglioma/ pheochromocytoma based on clinical criteria and biochemical/imaging findings; Hell J Nucl Med 2015 18(1): 63-65
Garrahy A. et al; A review of the management of positive biochemical screening for pheochromocytoma and paraganglioma: a salutary tale; Int J Clin Pract 2015 69(7): 802- 809
Carr J.C. et al; Discriminating pheochromocytomas from other adrenal lesions: the dilemma of elevated catecholamines; Am Surg Oncol 2013 20(12): 3855-3861
Pamporaki C. et al; Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma; Eur J Endocrinol 2014 170: 349-357
Barron J.; Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis; J Clin Pathol 2010 63: 669-674
Berkel van A. et al; Biochemical diagnosis of phaeochromocytoma and paraganglioma; Eur J Endocrinol 2014 170: R109-R119
Eisenhofer G. et al; Measurements of plasma methoxytyramine, normetanefrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma; Clin Chem 2011 57(3): 411-420
Därr R. et al; Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions; Clin Endocrinol 2014 80: 478-486
Eisenhofer G. et al; Rapid circulatory clearances and half-lives of plasma free metanephrines; Clin Endocrinol 2012 77: 484-487
Eisenhofer G. et al; Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results; JCEM 2003 88: 2656-2666
Stolk R.F. et al; Is the Excess Cardiovascular morbidity in Pheochromocytoma related to blood pressure or to Catecholamines?; J Clin Endocrinol Metab, March 2013, 98(3):1100- 1106
Galetta F. et al; Cardiovascular complications in patients with pheochromocytoma: A mini- review; Biomedicine & Pharmacotherapy 64 (2010) 505-509
Prejbisz A. et al; Cardiovascular manifestations of phaeochromocytoma; Journal of Hypertension 2011, 29:2049-2060
Wing L.A. et al; Paraganglioma in pregnancy: a case series and review of the literature; JCEM 2015
Biggar M.A. et al; Systematic review of phaeochromocytoma in pregnancy; British J Surg 2013 100: 182-190
Castinetti F. et al; Imaging and imaging-based treatment of pheochromocytoma and paraganglioma; Society of endocrinology 2015
Brito J. et al; The incremental benefit of functional imaging in pheochromocytoma/ paraganglioma: a systematic review; Endocrine 2015
Leung K. et al; Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging; Genitourinary Imaging 2012 200: 370-378
Rufini V. et al; Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review; Q J Nucl Med Imaging 2013 57: 122-133
Taïeb D. et al; EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma; Eur J Nucl Med Mol Imaging 2012 39: 1977-1995
Lentschener C. et al; Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal?; Eur J Endocrinol 165, 365-373
Fishbein L. et al; Pheochromocytoma/paraganglioma: review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma; J Clin hypertension 2013 15(6): 428-434
Choat H. et al; SDHB-associated Paraganglioma in a pediatric patient and literature review on hereditary pheochromocytoma-paraganglioma syndromes; Case reports in Endocrinology 2014
Waguespack S.G. et al; A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma; JCEM 2010 95(5): 2023-2037
Hulsteijn L.T. van et al; I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta- analysis; Clin Endocrinol 2014 80: 487-501
Livingstone M. et al; Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades; Ann Surg Oncol 2015
Barrett C. et al; risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review; Clin Endocrinol 2015
Mohammed A.A. et al; Target therapy in metastatic pheochromocytoma: current perspectives and controversies; Oncol Rev 2014 8: 249-249
Lowery A.J. et al; Molecular and therapeutic advances in the diagnoses and management of malignant Pheochromocytomas and paragangliomas; Oncologist 2013 18:391-407
q Baudin E. et al; Treatment of malignant pheochromocytoma and paraganglioma; Eur JEndocrinol 2014 171, r111-r122
Andersen K.F. et al; Malignant pheochromocytomas and paragangliomas- the importance of a multidisciplinary approach; Cancer treatment reviews 2011 37: 111-119
Sue M. et al; Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma; Eur J Endocrinol 2015 172(2): 89-95
Harari A. et al; Malignant pheochromocytoma: a review; Am J Sur 2011 201: 700-708
Ayala-Ramirez M. et al; Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators; JCEM 2011 96(3):717-725